UNIVEST FINANCIAL Corp Lowers Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

UNIVEST FINANCIAL Corp decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 32,041 shares of the medical equipment provider’s stock after selling 535 shares during the period. UNIVEST FINANCIAL Corp’s holdings in Lantheus were worth $2,866,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC raised its stake in Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after buying an additional 32,551 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new position in shares of Lantheus in the 3rd quarter worth $25,955,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Lantheus by 47.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after purchasing an additional 3,772 shares during the last quarter. Empirical Asset Management LLC bought a new stake in Lantheus during the fourth quarter valued at about $323,000. Finally, Focus Financial Network Inc. purchased a new position in Lantheus in the fourth quarter valued at about $292,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,109 shares of company stock valued at $6,110,806. 1.50% of the stock is owned by insiders.

Lantheus Stock Performance

Shares of LNTH opened at $99.77 on Wednesday. The stock has a 50-day moving average of $92.91 and a two-hundred day moving average of $96.45. The stock has a market cap of $6.83 billion, a P/E ratio of 16.60 and a beta of 0.38. Lantheus Holdings, Inc. has a one year low of $57.92 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LNTH. Truist Financial lifted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. Finally, B. Riley reduced their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.